L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease - PubMed (original) (raw)
Clinical Trial
. 1998 Mar 15;101(6):1408-14.
doi: 10.1172/JCI1155.
Affiliations
- PMID: 9502783
- PMCID: PMC508696
- DOI: 10.1172/JCI1155
Clinical Trial
L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease
J A Vita et al. J Clin Invest. 1998.
Abstract
The effective action of endothelium-derived nitric oxide (EDNO) is impaired in patients with atherosclerosis. This impairment has been attributed in part to increased vascular oxidative stress. EDNO action is improved by administration of ascorbic acid, a water-soluble antioxidant. Ascorbic acid is a potent free-radical scavenger in plasma, and also regulates intracellular redox state in part by sparing cellular glutathione. We specifically investigated the role of intracellular redox state in EDNO action by examining the effect of L-2-oxo-4-thiazolidine carboxylate (OTC) on EDNO-dependent, flow-mediated dilation in a randomized double-blind placebo-controlled study of patients with angiographically proven coronary artery disease. OTC augments intracellular glutathione by providing substrate cysteine for glutathione synthesis. Brachial artery flow-mediated dilation was examined with high-resolution ultrasound before and after oral administration of 4.5 g of OTC or placebo in 48 subjects with angiographically documented coronary artery disease. Placebo treatment produced no change in flow-mediated dilation (7.0+/-3.9% vs. 7.2+/-3.7%), whereas OTC treatment was associated with a significant improvement in flow-mediated dilation (6.6+/-4.4% vs. 11.0+/-6.3%; P = 0.005). OTC had no effect on arterial dilation to nitroglycerin, systemic blood pressure, heart rate, or reactive hyperemia. These data suggest that augmenting cellular glutathione levels improves EDNO action in human atherosclerosis. Cellular redox state may be an important regulator of EDNO action, and is a potential target for therapy in patients with coronary artery disease.
Similar articles
- Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease.
Gokce N, Keaney JF Jr, Frei B, Holbrook M, Olesiak M, Zachariah BJ, Leeuwenburgh C, Heinecke JW, Vita JA. Gokce N, et al. Circulation. 1999 Jun 29;99(25):3234-40. doi: 10.1161/01.cir.99.25.3234. Circulation. 1999. PMID: 10385496 Clinical Trial. - Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease.
Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA. Levine GN, et al. Circulation. 1996 Mar 15;93(6):1107-13. doi: 10.1161/01.cir.93.6.1107. Circulation. 1996. PMID: 8653830 Clinical Trial. - Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men.
Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Adams MR, et al. J Am Coll Cardiol. 1995 Oct;26(4):1054-61. doi: 10.1016/0735-1097(95)00257-9. J Am Coll Cardiol. 1995. PMID: 7560599 Clinical Trial. - The endothelium: a new target for therapy.
Cooke JP. Cooke JP. Vasc Med. 2000;5(1):49-53. doi: 10.1177/1358836X0000500108. Vasc Med. 2000. PMID: 10737156 Review. - Modulation of endogenous glutathione availability.
Wernerman J, Hammarqvist F. Wernerman J, et al. Curr Opin Clin Nutr Metab Care. 1999 Nov;2(6):487-92. doi: 10.1097/00075197-199911000-00010. Curr Opin Clin Nutr Metab Care. 1999. PMID: 10678678 Review.
Cited by
- Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders.
Ashique S, Mishra N, Mantry S, Garg A, Kumar N, Gupta M, Kar SK, Islam A, Mohanto S, Subramaniyan V. Ashique S, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug 28. doi: 10.1007/s00210-024-03392-1. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39196392 Review. - Cysteine Donor-Based Brain-Targeting Prodrug: Opportunities and Challenges.
Ni G, Hu Z, Wang Z, Zhang M, Liu X, Yang G, Yan Z, Zhang Y. Ni G, et al. Oxid Med Cell Longev. 2022 Feb 24;2022:4834117. doi: 10.1155/2022/4834117. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35251474 Free PMC article. Review. - Ebselen does not improve oxidative stress and vascular function in patients with diabetes: a randomized, crossover trial.
Beckman JA, Goldfine AB, Leopold JA, Creager MA. Beckman JA, et al. Am J Physiol Heart Circ Physiol. 2016 Dec 1;311(6):H1431-H1436. doi: 10.1152/ajpheart.00504.2016. Epub 2016 Oct 7. Am J Physiol Heart Circ Physiol. 2016. PMID: 27765750 Free PMC article. Clinical Trial. - Vitamin C: the known and the unknown and Goldilocks.
Padayatty SJ, Levine M. Padayatty SJ, et al. Oral Dis. 2016 Sep;22(6):463-93. doi: 10.1111/odi.12446. Epub 2016 Apr 14. Oral Dis. 2016. PMID: 26808119 Free PMC article. Review. - Arginine Thiazolidine Carboxylate Stimulates Insulin Secretion through Production of Ca2+-Mobilizing Second Messengers NAADP and cADPR in Pancreatic Islets.
Park DR, Shawl AI, Ha TG, Park KH, Kim SY, Kim UH. Park DR, et al. PLoS One. 2015 Aug 6;10(8):e0134962. doi: 10.1371/journal.pone.0134962. eCollection 2015. PLoS One. 2015. PMID: 26247205 Free PMC article.
References
- Clin Chem. 1972 Jun;18(6):499-502 - PubMed
- Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6702-6 - PubMed
- Proc Natl Acad Sci U S A. 1982 Oct;79(20):6246-9 - PubMed
- Clin Chem. 1983 Dec;29(12):2026-30 - PubMed
- Nature. 1986 Apr 3-9;320(6061):454-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources